Acquired resistance mechanisms of EGFR-TKI in advanced non-small cell lung cancer
10.3760/cma.j.issn.1673-422X.2015.06.016
- VernacularTitle:晚期非小细胞肺癌 EGFR-TKI 获得性耐药机制
- Author:
Yue ZHENG
;
Suju WEI
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Drug resistance,neoplasm;
Molecular targeted therapy
- From:
Journal of International Oncology
2015;(6):458-461
- CountryChina
- Language:Chinese
-
Abstract:
Since the development of molecular biology,the treatment of advanced non-small cell cancer is shifting from traditional chemotherapy into molecular targeted therapy with genotyping as a guide′s help.The most widely used is epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).With the appli-cation of EGFR-TKIs,the resistances to EGFR inhibitors are paid more and more attention,in recent years. The main mechanisms of acquired resistances are as follows:secondary mutation of the EGFR gene,amplifica-tion of c-MET,Her2 and other target genes,histological transformation,activation of the bypass mechanisms, loss of p53,the relief of negative feedback loops,overlap of mechanisms,etc.
